scispace - formally typeset
Journal ArticleDOI

Evaluation of clinical diagnostic criteria for neurofibromatosis 2

Reads0
Chats0
TLDR
None of the existing sets of criteria for neurofibromatosis 2 are adequate at initial assessment for diagnosing people who present without bilateral vestibular schwannomas as having NF2, particularly people with a negative family history of NF2.
Abstract
Background: Four sets of clinical diagnostic criteria for neurofibromatosis 2 (NF2) have been developed by groups of expert clinicians, but sensitivity has never been formally assessed. The sets of criteria differ for people without bilateral vestibular schwannomas, which are pathognomonic for NF2. Objective: To empirically evaluate the four existing sets of clinical diagnostic criteria for NF2. Methods: The study was based on 163 of 403 people in the United Kingdom NF2 registry (41%) who presented without bilateral vestibular schwannomas. The authors applied the sets of criteria to each person at initial assessment and at the most recent clinical evaluation (mean ± SE length of follow-up, 13 ± 1 years). Results: In people with “definite NF2” and a negative family history of NF2, the 1987 US NIH and 1991 NIH criteria each identify 78% of people at the most recent clinical evaluation but 0% at initial assessment. The National Neurofibromatosis Foundation (NNFF) criteria and the Manchester criteria each identify higher proportions at both time points (NNFF criteria, 91% and 10%; Manchester criteria, 93% and 14%), but the proportions at initial assessment are still low. Conclusions: None of the existing sets of criteria are adequate at initial assessment for diagnosing people who present without bilateral vestibular schwannomas as having NF2, particularly people with a negative family history of NF2. The authors recommend that a single, revised set of diagnostic criteria be devised to replace all of the existing sets of criteria.

read more

Citations
More filters
Journal ArticleDOI

Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service.

TL;DR: Estimates for NF1, NF2, FAP, and VHL are in line with previous estimates, and the first estimates of birth incidence and de novo mutation rate for Gorlin syndrome are provided.
Journal ArticleDOI

Neurofibromatosis type 2

TL;DR: Optimum treatment is multidisciplinary because of the complexities associated with management of the multiple, progressive, and protean lesions associated with the disorder.
Journal ArticleDOI

Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective

TL;DR: The pertinent diagnostic, clinical, and genetic symptoms of NF1 and NF2 are discussed and the current views on the pathogenesis of these neurocutaneous disorders in the wake of advances in molecular genetics and the development of mouse models of disease are examined.
Journal ArticleDOI

Neurofibromatosis type 2 (NF2): a clinical and molecular review.

TL;DR: Prognosis is adversely affected by early age at onset, a higher number of meningiomas and having a truncating mutation, with most patients facing substantial morbidity and reduced life expectancy.
Journal ArticleDOI

Contact-dependent inhibition of EGFR signaling by Nf2/Merlin

TL;DR: It is shown that upon cell–cell contact Merlin coordinates the processes of adherens junction stabilization and negative regulation of epidermal growth factor receptor (EGFR) signaling by restraining the EGFR into a membrane compartment from which it can neither signal nor be internalized.
References
More filters
Book

Data Analysis and Regression: A Second Course in Statistics

TL;DR: The assumption is made in this volume devoted to data analysis and regression that the student has had a 1st course in statistics and that attitudes and approaches are more important than the techniques this book can teach.
Journal ArticleDOI

The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.

TL;DR: The diagnostic criteria for neurofibromatosis 1 and neurof fibromaatosis 2, recommendations for the care of patients and their families at diagnosis and during routine follow-up, and the role of DNA diagnostic testing in the evaluation of these disorders are determined.
Journal ArticleDOI

A Clinical Study of Type 2 Neurofibromatosis

TL;DR: The clinical features, age at onset of symptoms and survival of 150 patients with type 2 neurofibromatosis were studied and there are marked inter-family differences in disease severity and tumour susceptibility.
Related Papers (5)